Skip to main content
OpenTrials

Clinical trial condition

Flaviviridae Infections

Explore clinical trials studying Flaviviridae Infections. Study availability and eligibility vary by location and protocol.

2,144 public trials 77 recruiting studies
Refine in advanced search Browse all conditions

Flaviviridae Infections trial results

Completed

A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection

NCT02496078

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • Local Institution Beijing, Beijing Municipality, China
  • Local Institution Beijing, Beijing Municipality, China
  • Local Institution Beijing, Beijing Municipality, China
  • Local Institution Beijing, Beijing Municipality, China
View all 29 locations
View Trial Details
Completed

An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis

NCT01609049

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Altay Region Aids Center Barnaul, Russia
  • Barnaul City Hospital #5; Therapy Barnaul, Russia
  • Chelyabinsk State Medical Academy; Infectious Diseases Chelyabinsk, Russia
  • Chita State Medical Academy Chita, Russia
View all 57 locations
View Trial Details
Completed

An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin

NCT01392742

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Mhat - Pleven; Clinic of Gastroenterology Pleven, Bulgaria
  • Umhat St. Georgi; Clinical of Gastroenterology Plovdiv, Bulgaria
  • MHAT Tokuda Hospital Sofia; Department of Gastroenterology at Clinic of Internal Deseases Sofia, Bulgaria
  • UMHAT Alexandrovska EAD; Gastroenterology Sofia, Bulgaria
View Trial Details
Completed

An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy

NCT01416610

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Lkh Hoergas-Enzenbach; Abt. Für Innere Medizin Gratwein, Austria
  • Lkh-Univ. Klinikum Graz Graz, Austria
  • Lkh innsbruck - univ. Klinikum innsbruck - Tiroler landeskrankenanstalten ges.m.b.h.; Innere Medizin Innsbruck, Austria
  • Klinikum Klagenfurt am Wörthersee; 2. Medizinische Abteilung Klagenfurt, Austria
View Trial Details
Completed

3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection

NCT01349465

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • Bakersfield, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Jacksonville, Florida, United States
View all 48 locations
View Trial Details
Completed

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

NCT01508130

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Cooper Green Hospital Birmingham, Alabama, United States
  • Univ. of Alabama at Birmingham; The Kirklin Clinic Birmingham, Alabama, United States
  • Liver Wellness Center Little Rock, Arkansas, United States
  • Loma Linda University Medical Center and Liver Center Loma Linda, California, United States
View all 66 locations
View Trial Details

Related conditions